Renal Anemia Drug Pipeline Analysis Report 2025

The National Institute of Diabetes and Digestive and Kidney Diseases estimates that 1 in 7 people affected by a kidney disease have anemia. In addition, more than 37 million United States adults may have chronic kidney disease. The rising prevalence of kidney diseases due to unhealthy dietary habits, sedentary lifestyle and increased alcohol indulgence complement the risk of renal anemia. Therefore, several companies are engaged in research and development to develop high-efficacy drugs to manage the condition, indicating a robust drug pipeline.

Report Coverage

The Renal anemia Drug Pipeline Report by the publisher gives comprehensive insights into ongoing renal anemia clinical trials. It covers various aspects related to the details of renal anemia drugs under development. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The renal anemia pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from renal anemia.

The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing renal anemia pipeline development activities are covered. Moreover, renal anemia collaborations and commercial assessments are offered, helping stakeholders to make informed decisions.

Renal Anemia Drug Pipeline Outlook

Renal anemia (also known as anemia of kidney disease) is a side effect of chronic kidney disease, leading to reduced production of erythropoietin (EPO). Erythropoietin is a vital hormone released by the kidneys and it helps in the production of red blood cells. Renal anemia gets worse with the progression of chronic kidney disease. Common symptoms include pale skin, dizziness, fatigue, shortness of breath or cold intolerance.

Renal anemia treatment alternatives include iron supplements and vitamins. However, medicines are advised to treat severe symptoms of the disease. In February 2023, GSK received the United States FDA approval for Jesduvroq (daprodustat), intended to treat chronic kidney disease associated anemia in adults on dialysis. Patients on hemodialysis may also receive a subcutaneous erythropoiesis-stimulating agent (ESA) for the treatment of anemia.

Renal Anemia - Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of renal anemia drug candidates based on several segmentations including:

By Phase

The pipeline assessment report covers 50+ drug analyses based on phase.

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

The renal anemia therapeutic assessment report covers 50+ drug analyses based on drug classes:

• Erythropoiesis-Stimulating Agents (ESAs)
• Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors (HIF-PHIs)
• Iron Supplements
• Vitamin Supplements

By Route of Administration

The pipeline assessment report covers 50+ drug analyses based on the route of administration.

• Oral
• Parenteral
• Others

Renal Anemia - Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase III covers a major share of the total clinical trials for renal anemia. There are around 206 drugs in phase III of renal anemia drugs.

Renal Anemia - Pipeline Assessment Segmentation, By Drug Classes

The drug molecules categories covered under renal anemia pipeline analysis include erythropoiesis-stimulating agents (ESAs), hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs), iron supplements and vitamin supplements. Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) are a relatively newer class of medications that stabilise hypoxia inducing factors and promote the production of erythropoietin naturally.

Renal Anemia Clinical Trials Therapeutic Assessment - Competitive Dynamics

The report for the renal anemia drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in renal anemia clinical trials:

• GlaxoSmithKline
• Hoffmann-La Roche
• Astellas Pharma Inc
• Kind Pharmaceuticals LLC
• Angde Biotech Pharmaceutical Co., Ltd.
• FibroGen
• Jiangsu HengRui Medicine Co., Ltd.
• Bayer
• Daiichi Sankyo

Renal Anemia - Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for renal anemia. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of renal anemia drug candidates.

AND017

As a part of a multi-center, open-label non-randomized, active-controlled Phase 2 study, this oral drug is under investigation to treat renal anemia. It is sponsored by Kind Pharmaceuticals LLC and is administered to patients with chronic kidney disease on dialysis.

FG-2216

Currently, in Phase 2 of an interventional study, FG-2216 is under evaluation for its efficacy and safety to treat patients with renal anemia who are not on dialysis or receiving erythropoietin. The study is sponsored by FibroGen and enrols 145 participants.

Roxadustat

Researchers at the Peking University First Hospital are conducting a Phase 4 multi-center, randomized, controlled study to assess the effect of roxadustate in patients on peritoneal dialysis. It is orally hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) with proven efficacy and safety in prior Phase 3 clinical trials.

PEG-EPO Injection

It is an experimental drug developed by Angde Biotech Pharmaceutical Co., Ltd. and is being explored for optimal dosage and administration to treat patients with renal anemia. PEG-EPO Injection is in Phase 2 of a multi-center, randomized, open-label, positive controlled clinical study that has an enrollment of 150 participants.

Reasons To Buy This Report

The Renal Anemia Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for renal anemia. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into renal anemia collaborations, regulatory environments, and potential growth opportunities within the treatment landscape.

Key Questions Answered in the Renal Anemia - Pipeline Insight Report

• Which companies/institutions are leading the renal anemia drug development?
• What is the efficacy and safety profile of renal anemia pipeline drugs?
• Which company is leading the renal anemia pipeline development activities?
• What is the current renal anemia commercial assessment?
• What are the opportunities and challenges present in the renal anemia drug pipeline landscape?
• What is the efficacy and safety profile of renal anemia pipeline drugs?
• Which company is conducting major trials for renal anemia drugs?
• Which companies/institutions are involved in renal anemia collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in renal anemia?

This product will be delivered within 3-5 business days.